pharmaphorum

OCTOBER 16, 2020

The repurposing of drugs is becoming more common, especially in the field of rare diseases. Now, as part of lifecycle management, pharmaceutical companies are looking more closely at drugs they have on their shelves. In the past, repurposing has mostly been driven by academics looking for new possibilities in generics.

Drug Development 105

Drug Development Immunity Immunization Pharmaceutical Companies 105

Pharmaceutical Technology

FEBRUARY 26, 2023

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Immunity 40

Immunity Immunization Pharmaceutical Companies Pharmaceutical Companies 40

Pharmaceutical Technology

FEBRUARY 26, 2023

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Immunity 40

Immunity Immunization Pharmaceutical Companies Pharmaceutical Companies 40

pharmaphorum

MARCH 10, 2022

Biologics product development has increased steadily over the past decade, with the volume of business forecast to double by 2030. Driven by advancements in technology, these complex therapeutics have already made waves in life sciences, providing revolutionary treatment options in oncology, immune conditions and rare diseases.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies Packaging Immunity 98

pharmaphorum

APRIL 28, 2022

For pharmaceutical companies, rare diseases present many challenges. AstraZeneca’s Alexion, which recently announced the building of a new rare disease development hub in Barcelona, is focused mostly on disorders of the complement system, a component of the immune system. How big pharma tackles rare diseases.

Immunity 59

Immunity Immunization Pharmaceutical Companies Pharmaceutical Companies 59

PharmaShots

MARCH 6, 2023

Traditionally patients were viewed by pharmaceutical companies as simply users of our products, nowadays they are considered partners working towards a collective goal. As a result of this progression, our industry developed the notion of patient-centricity.

Drug Development 40

Drug Development Immunity Immunization Pharmaceutical Companies 40

European Pharmaceutical Review

NOVEMBER 9, 2023

Following her presentation on age-related disease at BioFuture 2023, Executive Vice President of Drug Development for MyMD Pharmaceuticals ® , Jenna Brager, shares with EPR why the company’s next-generation tumour necrosis factor (TNF)-alpha inhibitor has potential in inflammatory and autoimmune disorders.

Drug Development 115

Drug Development Immunity Immunization Pharmaceutical Companies 115

European Pharmaceutical Review

APRIL 10, 2024

While this approach has shown to be safe and efficient in Clostridium difficile, the variability between donors may lead to random outcomes and responses in patients for immune-mediated diseases. Notably, from one donor to another, significant variations exist.

Immunity 95

Immunity Immunization Chemotherapy Diabetes 95

pharmaphorum

OCTOBER 12, 2022

“We founded Whitelab Genomics after realising the potential to use data, data science, and AI in a more systematic way to develop genomic therapies,” Del Bourgo says. Del Bourgo sees Debiopharm’s pharmaceutical industry expertise as an asset to the start-up as it expands its partnerships with new and international customers. “In

Drug Development 105

Drug Development Immunity Immunization Vaccines 105

pharmaphorum

NOVEMBER 2, 2020

Predicting protein structures would typically be a time-consuming process, but now scientists can use technology to better analyse viruses, thus helping in the search for a vaccine that can trigger an immune response. This knowledge is critical in understanding how effective certain drugs might be in treating the virus.

Vaccines 132

Vaccines Drug Development Diabetes Immunization 132

Pharmaceutical Technology

FEBRUARY 1, 2023

RSV researchers at major pharmaceutical companies are currently working to develop new RSV drugs to beat future waves of RSV infection and gain the first RSV vaccine FDA approval. Pharmaceutical companies are pushing to develop drugs and vaccines for RSV with these populations in mind.

Vaccines 64

Vaccines Drug Development Pharmaceutical Companies Pharmaceutical Companies 64

PharmaShots

FEBRUARY 21, 2023

Other radiotherapies under the company's pipeline include Humalutin and Alpha37. Nordic is advancing the development of CD37-targeted therapies for hematological cancers and immune diseases.

Dosage 56

Dosage Labelling Immunity Immunization 56

pharmaphorum

AUGUST 27, 2020

Over the past five to ten years US investors have focused on technology and internet companies, and relatively little on new biotech or pharmaceutical companies. The first is that the development of vaccines is utilising cutting edge technologies. Investment trends in the US influence investor appetite in the UK.

Vaccines 122

Vaccines Drug Pricing Compounding Immunity 122

Pharmaceutical Technology

AUGUST 26, 2008

It was once derided as the stuff of science fiction, but in recent years, biotechnology has emerged as an important growth area in pharmaceuticals. As understanding of biological systems has forged ahead, pharmaceutical companies have made increasing use of biotechnology in discovering and manufacturing new medicines.

Pharmaceutical Companies 40

Pharmaceutical Companies Pharmaceutical Companies Vaccines Drug Development 40

Pharmaceutical Technology

AUGUST 1, 2022

While the need for vaccines and drugs appeared more urgent than ever during the pandemic, it is possible that there will be more severe public health crises in years to come. AMR occurs when disease-causing bacteria become resistant or immune to the antibiotics used to treat them. million direct deaths in 2019 and an additional 4.95

Vaccines 93

Vaccines Pharmaceutical Companies Pharmaceutical Companies Chemotherapy 93

Pharmaceutical Technology

FEBRUARY 1, 2023

Pharmaceutical companies have been working on developing vaccines and other prophylactics for respiratory syncytial virus (RSV) since its discovery in 1956. Specific mutations can occur more rapidly when a virus is under immune selective pressure by prophylactic agents including mAbs and vaccines.

Vaccines 64

Vaccines Documentation Immunization Immunity 64